Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Dermatol Ther
; 35(1): e15192, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1506757
ABSTRACT
Atopic dermatitis (AD) is a common, chronic inflammatory condition with a substantial negative impact on the quality of life. Dupilumab, the first biologic approved for the treatment of moderate-to-severe AD, binds IL-4Rα and inhibits signaling of both IL-4 and IL-13. This study aimed to determine the real-life effectiveness and safety of dupilumab treatment in patients with moderate-to-severe AD. The results of the study indicates high effectiveness and safety of dupilumab in real-life conditions. The treatment was continued during the COVID-19 pandemic in most of the patients without any adverse outcome. The rate of conjunctivitis was higher compared to clinical trials, nevertheless treatment was not discontinued in any patients due to adverse effects.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dermatitis, Atopic
/
Antibodies, Monoclonal, Humanized
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Adult
/
Humans
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
Dth.15192
Similar
MEDLINE
...
LILACS
LIS